Status:
UNKNOWN
The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Liver Cirrhosis
Eligibility:
All Genders
30-60 years
Phase:
EARLY_PHASE1
Brief Summary
This study is a prospective study. We signed an informed consent form with patients with liver fibrosis and took tauroursodeoxycholic acid orally for half a year. After half a year, liver biopsy was p...
Detailed Description
Tauroursodeoxycholic acid is an effective component of bear bile, which has obvious curative effects in the treatment of gallstones and liver diseases. In recent years, the research field of taurourso...
Eligibility Criteria
Inclusion
- Clinical diagnosis of liver cirrhosis and liver fibrosis in patients requiring medical treatment.
Exclusion
- Patients with end-stage cirrhosis, liver failure, etc. who need liver transplantation.
Key Trial Info
Start Date :
March 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04727320
Start Date
March 5 2021
End Date
July 30 2021
Last Update
March 9 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.